FLT3 and acute myeloid leukemia: The addition of gilteritinib to venetoclax and azacitidine in FLT3-mutated AML achieved a complete remission rate of 90% in newly diagnosed patients, with 65% of evaluable patients achieving FLT3-ITD measurable residual disease negativity.